Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
27 Sep 2024
// BUSINESSWIRE
31 May 2024
// INDINPHARMAPOST
https://www.indianpharmapost.com/drug-approval/bluerock-therapeutics-receives-fda-rmat-designation-for-parkinsons-disease-cell-therapy-candidate-bemdaneprocel-15706
06 Mar 2024
// PRESS RELEASE
https://www.bayer.com/media/en-us/bluerock-therapeutics-phase-i-clinical-trial-for-parkinsons-disease-continues-to-show-positive-trends-at-18-months/
23 Jan 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics-302041694.html
02 Oct 2023
// PRESS RELEASE
https://www.bayer.com/en/us/news-stories/investigational-cellular-therapy-bemdaneprocel
28 Aug 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/bluerocks-phase-i-study-with-bemdaneprocel-in-patients-with-parkinsons-disease-meets-primary-endpoint-301910863.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?